Articles tagged with "adalimumab"

First Biosimilar to Adalimumab (Humira) Enters the U.S. Market After Years of Legal Battles

January 31, 2023 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved

November 17, 2021 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira

October 19, 2021 • By U.S. Food & Drug Administration

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

October 14, 2021 • By Vanessa Caceres

Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care

October 14, 2021 • By Sarah D. Bayefsky, MD, Kimberly DeQuattro, MD, & Rebecca E. Sadun, MD, PhD

Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate

March 9, 2021 • By Vanessa Caceres

Oxford University to Study Adalimumab as Potential COVID-19 Treatment

September 30, 2020 • By Josephine Mason & Kate Kelland

Biologic Spending & Price Trends

January 28, 2020 • By Arthritis & Rheumatology

Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases

October 9, 2019 • By Caroline Humer

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

August 16, 2019 • By Mary Choy, PharmD, BCGP, FASHP

1
2
3
…
9
Next Page »